

REVIEW OF DECISIONS

BOARD MEETING

4-5 December 2019, Delhi, India



Reach every child

www.gavi.org

Decision 1: Consent Agenda: Sudan's eligibility for Gavi support in 2020

The Gavi Alliance Board:

Approved, exceptionally, that the determination of Sudan's eligibility for 2020 will be based on the latest GNI data point instead of the average GNI per capita over the past three years.

Decision 2: Consent Agenda: Board Vice Chair appointment

The Gavi Alliance Board:

- a) **Appointed** Sarah Goulding as Board member representing Australia on the donor constituency anchored by the United States in the seat currently held by Irene Koek of the United States, effective 1 January 2020 and until 31 December 2021
- b) **Appointed** Irene Koek as Alternate Board representing the United States on the donor constituency anchored by the United States, effective 1 January 2020 and until 31 December 2021
- c) **Appointed** Sarah Goulding as Vice Chair of the Board with individual signatory authority, effective 1 January 2020 and until 31 December 2021

Decision 3: Consent Agenda: Amendment to Governance Committee Charter

The Gavi Alliance Board:

Amended Article 2.A of the Gavi Alliance Governance Committee Charter to read as follows:

“... If for any reason the Board Vice Chair is not from among any of the constituencies designated above, or for any other reason determined by the Committee, the Committee shall be exceptionally expanded to 13.”

Decision 4: Consent Agenda: Board Committee Chair appointments

The Gavi Alliance Board:

- a) **Reappointed** the following as Chair of the Investment Committee:
 - Stephen Zinser until 30 June 2020
- b) **Reappointed** the following as Chair of the Audit and Finance Committee:
 - David Sidwell until 31 December 2020
- c) **Reappointed** the following as Chair of the Programme and Policy Committee:
 - Helen Rees until 31 December 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (1/10)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Maty Dia** as Board Member representing the civil society organisations constituency in the seat formerly held by Craig Burgess, effective immediately and until 31 December 2021.
- **Jan Paehler** as Board Member representing the European Commission on the donor constituency anchored by Germany in the seat currently held by Harriet Ludwig of Germany, effective 1 January 2020 and until 31 December 2020.
- **Roger Conner** as Board Member representing the vaccine industry industrialised countries in the seat currently held by Susan Silbermann, effective 1 August 2020 and until 31 July 2023

Decision 5: Consent Agenda: Board and Board Committee member appointments (2/10)

b) **Reappointed** the following Board Members:

- **Daniel Graymore** as Board Member representing the United Kingdom on the donor constituency anchored by the United Kingdom, effective 1 January 2020 and until 31 December 2022.
- **Margaret (Peggy) Hamburg** as an Unaffiliated Board Member, effective 1 January 2020 and until 31 December 2022.

Decision 5: Consent Agenda: Board and Board Committee member appointments (3/10)

c) **Appointed** the following Alternate Board Members:

- **Frank Mahoney** as Alternate Board Member representing the civil society organisations constituency in the seat currently held by Maty Dia, effective immediately and until 31 December 2019.
- **An Vermeesch** as Alternate Board Member representing the vaccine industry industrialised countries in the seat currently held by Julie Hamra, effective immediately and until 31 July 2023.
- **Joan Valadou** as Alternate Board Member representing France on the donor constituency anchored by Germany in the seat currently held by Jan Paehler of the European Commission, effective 1 January 2020 and until 31 December 2020.

d) **Reappointed** the following Alternate Board Member:

- **Susan Elden** as Alternate Board member to Daniel Graymore representing the United Kingdom, effective 1 January 2020 and until 31 December 2022.

Decision 5: Consent Agenda: Board and Board Committee member appointments (4/10)

- e) **Appointed** the following to the Audit and Finance Committee effective 1 January 2020:
- **David Sidwell** (Board Member) until 31 December 2020
 - **Teresa Ressel** (Board Member) until 31 December 202
 - **Beniamin Carcani** (Committee Delegate) until 31 December 2021
 - **Etleva Kadilli** (Alternate Board Member) until 31 December 2021
 - **Kwaku Agyeman-Manu** (Board Member) until 31 December 2020
 - **Emmanuel Maina Djoulde** (Committee Delegate) until 31 December 2021
 - **Andreas Karlsberg Pettersen** (Committee Delegate) until 31 December 2021
 - **Irene Koek** (Alternate Board Member) until 31 December 2021
 - **Gisella Berardi** (Committee Delegate) until 31 December 2021
 - **Tom Morrow** (Committee Delegate) until 31 December 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (5/10)

- f) **Appointed** the following to the Investment Committee effective 1 January 2020:
- **Stephen Zinser** (Board Member) until 30 June 2020
 - **David Sidwell** (Board Member) until 31 December 2020
 - **Afsaneh Beschloss** (Board Member) until 31 December 2021
 - **Margaret (Peggy) Hamburg** (Board Member) until 31 December 2021
 - **Matthias Reinicke** (Committee Delegate) until 31 December 2021
 - **William Roedy** (Board Member) until 31 July 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (6/10)

- g) **Appointed** the following to the Evaluation Advisory Committee effective 1 January 2020:
- **Marta Nunes** (Board Member) until 31 December 2020
 - **Maty Dia** (Board Member) until 31 December 2021
 - **Zulfiqar A. Bhutta** (Independent Expert) until 31 December 2021
 - **Jeanine Condo** (Independent Expert) until 31 December 2021
 - **Juan Pablo Gutiérrez** (Independent Expert) until 31 December 2021
 - **Mira Johri** (Independent Expert) until 31 December 2021
 - **Ezzedine Mohsni** (Independent Expert) until 31 December 2021
 - **Viroj Tangscharoensathien** (Independent Expert) until 31 December 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (7/10)

h) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 January 2020:

- **Ngozi Okonjo Iweala** (Board Chair) until 31 December 2020
- **Sarah Goulding** (Board Member) until 31 December 2021
- **Etleva Kadilli** (Alternate Board Member) until 31 December 2021
- **Muhammad Pate** (Board Member) until 31 December 2021
- **Violaine Mitchell** (Alternate Board Member) until 31 December 2021
- **Amir Aman Hagos** (Board Member) until 31 December 2020
- **Arsen Torosyan** (Board Member) until 31 December 2020
- **Daniel Graymore** (Board Member) until 31 December 2021
- **Jan Paehler** (Board Member) until 31 December 2020
- **Irene Koek** (Board Member) until 31 December 2021
- **Maty Dia** (Board Member) until 31 December 2021
- **David Sidwell** (Board Member) until 31 December 2020
- **Helen Rees** (Board Member) until 31 December 2021
- **Seth Berkley** (Board Member) until 31 December 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (8/10)

i) Appointed the following to the Governance Committee effective 1 January 2020:

- **Sarah Goulding** (Board Vice Chair) until 31 December 2021
- **Bill Roedy** (Board Member) until 31 July 2021
- **Stephen Zinser** (Board Member) until 30 June 2020
- **Omar Abdi** (Board Member) until 31 December 2021
- **Orin Levine** (Board Member) until 31 December 2021
- **Ferozuddin Feroz** (Board Member) until 31 December 2020
- **Tamar Garbunia** (Committee Delegate) until 31 December 2021
- **Daniel Graymore** (Board Member) until 31 December 2021
- **Jan Paehler** (Board Member) until 31 December 2020
- **Megan Cain** (Board Member) until 31 December 2020
- **Maty Dia** (Board Member) until 31 December 2021
- **Susan Silbermann** (Board Member) until 31 July 2020
- **Seth Berkley** (Board Member) until 31 December 2021

j) Appointed the following to the Governance Committee effective 1 August 2020:

- **Roger Conner** (Board Member) until 31 July 2021

Decision 5: Consent Agenda: Board and Board Committee member appointments (9/10)

k) **Appointed** the following to the Programme and Policy Committee effective 1 January 2020:

- **Helen Rees** (Board Member) until 31 December 2021
- **Michael Kent Ranson** (Alternate Board Member) until 31 December 2021
- **Robin Nandy** (Committee Delegate) until 31 December 2021
- **Kate O'Brien** (Committee Delegate) until 31 December 2021
- **Violaine Mitchell** (Alternate Board Member) until 31 December 2021
- **Ahmed Abdallah** (Committee Delegate) until 31 December 2021
- **Vandana Gurnani** (Committee Delegate) until 31 December 2021
- **Edna Yolani Batres** (Alternate Board Member) until 31 December 2021
- **Joan Valadou** (Alternate Board Member) until 31 December 2020
- **Lene Lothe** (Alternate Board Member) until 31 December 2020

Decision 5: Consent Agenda: Board and Board Committee member appointments (10/10)

- **Susan Elden** (Alternate Board Member) until 31 December 2021
- **Naomi Dumbrell** (Committee Delegate) until 31 December 2021
- **Lubna Hashmat** (Committee Delegate) until 31 December 2021
- **William Schluter** (Alternate Board Member) until 31 December 2020
- **Joan Benson** (Committee Delegate) until 31 December 2021
- **Mahima Datla** (Alternate Board Member) until 31 December 2020
- **Seth Berkley** (Board Member) until 31 December 2021
- **Alejandro Cravioto** (Independent Expert) until 31 December 2021

Decision 6: Consent Agenda: Independent Review Committee appointments

The Gavi Alliance Board:

Ratified the emergency appointment of 11 IRC members by the Chief Executive Officer in concurrence with the Chair of the Programme and Policy Committee (PPC) under Article 5.1.1 of the By-Laws, whose names are listed in Annex A to Doc 05c to the 25 November 2019 Governance Committee meeting, for a term effective 12 August 2019 until 31 March 2022.

Decision 7: Consent Agenda: Amendment to Gavi Statutes

The Gavi Alliance Board:

Amended Article 4 of the French-language version of the Gavi Statutes to read as follows:

Le siège statutaire de la Gavi Alliance sera dans le Canton de Genève, en Suisse. Le Conseil Conseil reçoit pleins pouvoirs pour déplacer le siège de la Gavi Alliance, avec l'accord préalable de l'Autorité de Surveillance.

Decision 8: Financial update, including forecast (1/2)

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee has reviewed the financial implications of the recommendations to be made to the Programme and Policy Committee as set out in Figures 1 to 5 of Doc 02a to the Audit and Finance Committee of 10 October 2019 (Financial Update) and concluded that these recommendations could be approved by the Board in accordance with the Programme Funding Policy;
- b) **Approved** the Financial Forecast for the period 2016-2020 as set out in Section B of Doc 06a;
- c) **Approved** the Financial Forecast for the period 2021-2025 as set out in Section B of Doc 06a, which is dependent on resources becoming available for that period; and

Decision 8: Financial update, including forecast (2/2)

- d) **Authorised** the Gavi Secretariat to allot funding in 2020 for new programmes and for the continuation and adjustment of funding to existing programmes, in accordance with the Programme Funding Policy. In making such allotment decisions, the Secretariat will take into consideration the outcome of Gavi's replenishment in June 2020.

Decision 9: Partners' Engagement Framework & Secretariat Budget 2020 (1/2)

The Gavi Alliance Board:

- a) **Approved** within the overall amount of US\$ 253.4 million for 2020 for the Partners' Engagement Framework, the following allocations:
- (i) US\$ 165.4 million for PEF Partners to support Targeted Country Assistance, Special Investments in Strategic Focus Areas and Foundational Support;
 - (ii) US\$ 0.4 million in fees for UNICEF Supply Division to procure yellow fever diagnostic surveillance equipment;
 - (iii) US\$ 24.0 million for investing in Partnerships in Innovation to be administered by the Secretariat;
 - (iv) US\$ 18.5 million for Impact Assessments and Evaluations to be administered by the Secretariat;

Decision 9: Partners' Engagement Framework & Secretariat Budget 2020 (2/2)

- b) **Approved** US\$ 110.3 million for Secretariat Engagement;
- c) **Approved** US\$ 0.5 million for capital expenditure budgets to implement the Secretariat's part of the Gavi Engagement Framework.

Decision 10: Malaria Vaccine Implementation Programme

The Gavi Alliance Board:

Approved an amount up to US\$ 11.6 million to continue the malaria vaccine implementation programme from 2021-2023.

Decision 11: Malaria

The Gavi Alliance Board:

- a) **Noted** that to enable long-term sustainable supply, GSK has contractually committed to WHO and PATH under the Collaboration Agreement for the Malaria Vaccine Implementation Program to pursue the transfer of the RTS,S vaccine to another vaccine manufacturer, excluding GSK's proprietary adjuvant, which GSK has agreed to supply within certain volume projections;
 - b) **Requested** the Secretariat to work with stakeholders to identify third-parties to cost share whereby Gavi's financial risk should be minimised or reduced to zero to provide for an investment for continued production of RTS,S bulk antigen pending a WHO policy decision and Gavi investment case for broader roll-out; and
 - c) **Approved** an investment for continued production of RTS,S bulk antigen between Gavi and third-parties whereby Gavi's financial risk exposure should be minimised as much as possible, with reassessment of support on an annual basis, subject to the final terms being reviewed and endorsed by the Market Sensitive Decisions Committee; noting that it shall not pre-empt or influence a Board decision on support for broader roll out of RTS,S and shall not set a precedent for any future vaccine investments.
-

Decision 12: Gavi's engagement in Ebola vaccine (1/3)

The Gavi Alliance Board:

- a) **Approved** the opening of a funding window for the establishment of an Ebola programme for licensed vaccines used for i) reactive and preventive vaccination in an outbreak setting through an emergency stockpile and ii) preventive vaccination in a non outbreak setting, contingent on WHO prequalification of vaccine and SAGE recommendation, in line with Board approved policies and decisions with adjustments laid out under b), c) and d);
- b) **Approved** Gavi support for vaccines for preventive use without a co financing obligation for Gavi eligible countries with the co-financing policy for Ebola vaccine subject to review after two years from start of programme;
- c) **Approved** Gavi operational cost support for both reactive and preventive vaccination that is tailored to each country based on context;

Decision 12: Gavi's engagement in Ebola vaccine (2/3)

- d) **Approved** the principle of providing non Gavi eligible countries access to vaccines for preventive vaccination, where possible. These countries would bear the cost of the vaccine;
- e) **Noted** the financial implications associated with the above approvals for vaccine procurement, operational cost support and Secretariat and partner resources for 2020 is expected to be approximately US\$ 9 million and for 2021-2025 is expected to be approximately US\$ 169 million. Gavi will seek to absorb the Secretariat and PEF-related components in the 2020 estimated costs within the 2020 budget submission;
- f) **Noted** that the Secretariat will work with partners to further develop processes to enable allocation of vaccines and operational cost support for both reactive and preventive use;

Decision 12: Gavi's engagement in Ebola vaccine (3/3)

- g) **Approved** retaining the operational cost and health system support component of the 2014 Ebola envelope for the interim period before a licensed vaccine is available in order to provide operational support for use of investigational vaccines and closing the remainder of the 2014 Ebola envelope; and
- h) **Noted** the remaining balance of the operational cost and health systems support component of the 2014 Ebola envelope of US\$ 52.4 million.

Decision 13: Gavi 5.0: Funding Policy Review (1/2)

The Gavi Alliance Board **approved** the following, which will be incorporated into Gavi's policies in June 2020:

- a) using the **latest point estimate of GNI per capita** alongside the average GNI per capita over the past three years to determine countries' eligibility for support; and for countries (re)gaining eligibility, adoption of a tailored approach based on the country context;
- b) adoption of an approach to **tailor the accelerated transition** phase as described in Annex B to Doc 09;
- c) **removing the programme filter** requiring 70% or higher coverage of the 3rd dose of DTP-containing vaccine for a country to access new support for select vaccines (as set out in the Eligibility & Transition Policy);
- d) calculating **vaccine co-financing** for all countries based on the share of doses needed by a country;

Decision 13: Gavi 5.0: Funding Policy Review (2/2)

- e) adopting an approach to apply co-financing flexibilities as described in Annex B to Doc 09, in countries facing **severe fiscal distress** and countries facing a **humanitarian crisis**;
- f) allocating HSS resources according to four criteria: **equity** (number of zero-dose children), **coverage** (number of underimmunised children), **ability to pay** (GNI pc), and **population in need** (birth cohort), with all four criteria equally weighted;
- g) removing the **cap** of US\$ 100 million over five years currently applied to total country HSS ceilings, but retaining the floor of US\$ 3 million;
- h) **integrating** support for CCEOP into HSS support; and
- i) discontinuing the mechanism of awarding **Performance Payments** (as set out in the HSIS Support Framework).

Decision 14: Risk Management Update

The Gavi Alliance Board:

Approved the Risk & Assurance Report 2019 attached as Annex A to Doc 11.

Gavi Board Meetings 2020

- **19 March, Teleconference, 13.30-15.30 GVA**
- **11 May, Teleconference, 14.30-16.30 GVA**
- **24-25 June, Geneva**
- **16-17 December, TBD**

Thank you



www.gavi.org